MEN11467 - CAS:214487-46-4 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	MEN11467
英文名称:	MEN11467
别名:	N-[(1S,2R)-2-[[(2R)-2-[methyl-[2-(4-methylphenyl)acetyl]amino]-3-naphthalen-2-ylpropanoyl]amino]cyclohexyl]-1H-indole-3-carboxamide
CAS No:	214487-46-4	分子式:	C₃₈H₄₀N₄O₃	分子量:	600.75
CAS No:	214487-46-4
分子式:	C₃₈H₄₀N₄O₃
分子量:	600.75

点击下载产品说明书(PDF)

M11656 MEN11467 (psaitong)

相关产品

SB218795
CAS No：174635-53-1
Neurokinin antagonist 1
CAS No：214487-45-3
Vofopitant
CAS No：168266-90-8
SB-222200
CAS No：174635-69-9
Vofopitant dihydrochloride
CAS No：168266-51-1
Talnetant
CAS No：174636-32-9

包装规格：

1mg 5mg in glass bottle

产品描述：

基本信息

产品编号：	M11656
产品名称：	MEN11467
CAS:	214487-46-4	储存条件	粉末	-20℃	四年
分子式：	C38H40N4O3		溶于液体	-80℃	二年
分子量：	600.75
化学名：	N-[(1S,2R)-2-[[(2R)-2-[methyl-[2-(4-methylphenyl)acetyl]amino]-3-naphthalen-2-ylpropanoyl]amino]cyclohexyl]-1H-indole-3-carboxamide
Solubility (25°C)：
体外:	DMSO
	Ethanol
	Water
体内(现配现用):
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

生物活性

产品描述	一种有效的选择性拟肽速激肽 NK 1 受体拮抗剂。
靶点	Tachykinin NK1 receptor
体外研究	MEN11467 potently inhibits the binding of [3H] substance P (SP) to tachykinin NK1 receptors in the IM9 limphoblastoid cell line (pKi=9.4±0.1).MEN11467 is highly specific for the human tachykinin NK1 receptors,since it has negligible effects (pKi<6) on the binding of specific ligands to tachykinin NK2 or NK3 receptors and to a panel of 30 receptors ion channels unrelated to tachykinin receptors.The antagonism exerted by MEN11467 at tachykinin NK1 receptors is insurmountable in saturation binding experiments,both KD and Bmax of SP are significantly reduced by MEN11467 (0.3-10nM).In the guinea-pig isolated ileum,MEN11467 (0.03-1nM) produces a nonparallel rightward shift of the concentration-response curve to SP methylester with a concomitant reduction of the Emax to the agonist (pKB=10.7±0.1).Moreover the antagonist activity of MEN11467 is hardly reversible despite prolonged washout.The pseudopeptide tachykinin NK1 receptor antagonist, MEN11467 is used to study tachykininergic involvement in antigen-induced mucus secretion in ferret trachea in vitro.MEN11467 (1 nM-10μM) inhibits [Sar9]SP-induced 35SO4,output in a concentration-dependent manner with an approximate IC50 of 0.3μM.
体内研究	MEN11467 produces a long lasting (>2-3h) dose-dependent antagonism of bronchoconstriction induced by the selective tachykinin NK1 receptor agonist,[Sar9,Met(O2)11]SP in anaesthetized guinea-pigs (ID50s=29±5,31±12 and 670±270μg/kg,after intravenous,intranasal and intraduodenal administration,respectively),without affecting bronchoconstriction induced by methacholine.After oral administration MEN11467 produces a dose-dependent inhibition of plasma protein extravasation induced in guinea-pig bronchi by [Sar9,Met(O2)11] (ID50=6.7±2mg/kg) or by antigen challenge in sensitized animals (ID50=1.3mg/kg).After i.v.administration MEN11467 weakly inhibits the GR 73632 induced foot tapping behaviour in gerbil (ED50=2.96±2mg/kg),indicating a poor ability to block central tachykinin NK1 receptors.Treatment with MEN11467 (1mmol/kg twice weekly for 2 weeks) results in a temporary growth arrest of the U373 MG xenograft that last for about 10 days until the last MEN11467 administration (TVI%=56).Thereafter,the tumor start to regrow. MEN11467 antitumor activity is partially reverted by the simultaneous administration of an equimolar dose of exogenous substance P (SP),suggesting the specificity of tachykinin NK1 receptor activation in glioma growth. Prolonged s.c. treatment with a higher MEN11467 dose (1.7mmol/kg at five times a week for 6 weeks) completely inhibits the growth of U373 MG tumor for the entire length of the experiment,even following administration of a low exogenous SP dose.After 6 weeks, the tumor mass is not increased compared to the untreated control with TVI%=96%.

推荐实验方法(仅供参考)

动物实验:

Mice

Female athymic nu/nu nude mice,5-7 weeks old are used. Tumor xenografts are obtained by subcutaneous (s.c.) injection of 2×107 U373 MG cells or 107 A2780 cells into the right flanks of female nude mice.Five days after tumor cell inoculation U373 MG or A2780 tumor-bearing mice are randomly divided into different groups (six animals per group) and treated intravenously (i.v.) or s.c.as reported in Results.In local treatments all the s.c.injections of MEN11467 are sited at about 5mm from the tumor.MEN11467 or MEN 11149 are administered at doses that have been previously shown to produce a complete blockade of tachykinin NK1-mediated response (bronchoconstriction) elicited by a systemic administration of Sar 9SP,a selective agonist of NK1 tachykinin receptor in guinea pig.The tumors are measured in two diameters and the tumor volume (TV) is calculated. Optimal tumor volume inhibition percent (TVI%) in treated over control mice is evaluated.

保存条件：

-20℃

UN码：

HazardClass：

危害声明：

安全说明：

搜索质检报告(COA)

参考文献 & 客户发表文献